Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Zomaril

Executive Summary

Schizophrenia drug iloperidone shows "at 16 mg level a significantly different efficacy level as compared to placebo," Novartis said during an Oct. 11 teleconference. "The Pink Sheet" (Oct. 16, p. 14) incorrectly reported that the comparator agent in the trial was J&J's Risperdal. Novartis licenses Zomaril from South San Francisco-based Titan Pharmaceuticals. "Novartis' timeline for NDA submission for Zomaril is fourth quarter 2001," Titan said
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS036784

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel